Near future
No Result
View All Result
30 September 2023
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+
Understand, anticipate, improve the future.
CES2023 / Coronavirus / Russia-Ukraine
Near future
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+

Understand, anticipate, improve the future.

No Result
View All Result
Medicine

Aducanumab, anti-Alzheimer's drug approved, but doubts remain

Aducanumab could represent a revolution for all Alzheimer's patients, but for now it represents only an element of controversy

December 26 2021
Gianluca RiccioGianluca Riccio
⚪ 3 minutes
Share852Pin193Tweet533SendShare149ShareShare107
aducanumab

READ IN:

At different times, the US Food and Drug Administration's approval of the drug aducanumab would have been celebrated as one of the great therapeutic advances of 2021. After all, it is the first drug to target the causes of Alzheimer's, the most common form of dementia. .

L'Alzheimer it affects millions of people in the world: 1,4 million in Italy alone. There is a handful of medications that temporarily dull his symptoms, but none could really slow his advance.

Aducanumab, uphill start

Despite the premises, the FDA approval has become one of the most controversial. It all starts in March 2019, when the developers of aducanumab, the American Biogen and the Japanese Eisai, stop two large clinical trials after an independent monitoring committee determines that the drug shows no clinical benefit.

Yet the drug seemed to be doing its job: ridding patients' brains of amyloid plaques, the abnormal protein deposits characteristic of Alzheimer's. However, as it is still unclear whether or not amyloid causes the disease, the matter has been put on hold. However, Biogen did not give up: after further analysis, she resubmitted her case in November 2020.

Another resounding rejection, with 10 out of 11 votes against: "there is no substantial evidence of the effect of aducanumab," the biostatistic office of the FDA said. The risks presented by aducanumab seemed to outweigh the benefits.

The article continues after the related links

New cholesterol-lowering drug also cuts obesity in tests on mice

Jelly Drops, water bonbons to hydrate those suffering from Alzheimer's

End of games for aducanumab? No.

The FDA could have concluded things there. Instead, the agency gave the green light to aducanumab last June, deeming it "reasonably likely to anticipate clinical benefit." Biogen is required to set up another study, with results expected by 2030: in the meantime, it can sell its product (under the trade name aduhelm) to any patient with Alzheimer's.

On the same day, the company announced the drug's list price in the US: over 50.000 euros a year.

aducanumab
A pack of Aduhelm, the commercial name of the very salty anti-Alzheimer's therapy with still uncertain effects.

And now it's chaos

Patient associations and researchers have cheered the FDA's decision, hoping that the Biogen drug will work. Three members of the supervisory board's executive board resigned in protest, and it seems like just the beginning.

Even the US Congress has launched two investigations by as many commissions as to how Aducanumab was approved and why it costs so much.

A report emerged (in the press) denouncing a "pressure" campaign initiated by Biogen to influence the FDA.

Another investigation, this time requested by the FDA commissioner himself, Janet Woodcock. Meanwhile, some medical centers say they will not prescribe the drug.

Will it work?

By 2030, when there are reliable results, will we count more successes or more harm from this drug? In Europe, the EMA rejected the use of the drug, too early to know if it's worth it. In the US, doctors are making their own decisions, generally informing patients.

"When I talk to patients about aducanumab, I include a narrative of the events that led to its approval," he says. Jason Karlawish, a geriatrician at the University of Pennsylvania's Perelman School of Medicine. 

"People need to understand where something comes from." 

Already. They must also be able to trust, though.

Tags: alzheimerdrugsFDA

Latest news

  • Lawk One AR Glasses: augmented reality for high-tech cyclists
  • SolarisFloat, the solar island that follows the sun to maximize energy
  • Solar Airship One: The airship that flies non-stop around the world
  • Optivolt revolutionizes solar: efficient panels even in the shade
  • Callboats, Helsinki launches autonomous and electric taxis on water
  • China aims underground: a moon base in lava tubes
  • On Mars in 26 days with the new airbrush solar sail
  • Amazon invests in Anthropic: the AI ​​war rages on
  • Smile: Drug that regrows teeth reaches clinical trials
  • Without a brake from the institutions, will AI lead to private neo-feudalism?


GPT Chat Megaeasy!

Concrete guide for those approaching this artificial intelligence tool, also designed for the school world: many examples of applications, usage indications and ready-to-use instructions for training and interrogating Chat GPT.

To submit articles, disclose the results of a research or scientific discoveries write to the editorial staff

Enter the Telegram channel of Futuroprossimo, click here. Or follow us on Instagram, Facebook, Twitter, Mastodon e LinkedIn.

FacebookTwitterInstagramTelegramLinkedInMastodonPinterestTikTok

The daily tomorrow.


Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

  • Environment
  • Architecture
  • Artificial intelligence
  • Gadgets
  • concepts
  • Design
  • Medicine
  • Spazio
  • Robotica
  • Work
  • Transports
  • Energy
  • Edition Francaise
  • Deutsche Ausgabe
  • Japanese version
  • English Edition
  • Portuguese Edition
  • Read more
  • Spanish edition

Subscribe to our newsletter

  • The Editor
  • Advertising on FP
  • Privacy Policy

© 2023 Near future - Creative Commons License
This work is distributed under license Creative Commons Attribution 4.0 International.

No Result
View All Result
Understand, anticipate, improve the future.
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+